A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse

ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer

Marth, Christian
Vergote, Ignace
Scambia, Giovanni
Oberaigner, Willi
Clamp, Andrew
Berger, Regina
Kurzeder, Christian
Colombo, Nicoletta
Vuylsteke, Peter
Lorusso, Domenica
Hall, Marcia
Renard, Vincent
Pignata, Sandro
Kristeleit, Rebecca
Altintas, Sevilay
Rustin, Gordon
Wenham, Robert M
Mirza, Mansoor Raza
Fong, Peter C
Oza, Amit
Monk, Bradley J
Ma, Haijun
Vogl, Florian D
Bach, Bruce A

November 2016

Trebananib, a peptide-Fc fusion protein, inhibits angiogenesis by inhibiting binding of angiopoietin...

Farletuzumab for NSCLC: Exploiting a well-known metabolic pathway for a new therapeutic strategy

Bronte G.
Lo Vullo F.
Pernice G.
Galvano A.
Fiorentino E.
Cicero G.
Bazan V.
Rolfo C.
Russo A.

January 2015

Introduction: The therapeutic options for NSCLC are limited barring targeted drugs, such as EGFR tyr...

Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications

Vergote, Ignace
Marth, Christian
Coleman, Robert L

January 2015

Folate can be transported into the cell by the reduced folate carrier (RFC), the proton-coupled fola...

A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse

Vergote, Ignace
Armstrong, Deborah
Scambia, Giovanni
Teneriello, Michael
Sehouli, Jalid
Schweizer, Charles
Weil, Susan C
Bamias, Aristotelis
Fujiwara, Keiichi
Ochiai, Kazunori
Poole, Christopher
Gorbunova, Vera
Wang, Wenquan
O'Shannessy, Daniel
Herzog, Thomas J

July 2016

Farletuzumab is a humanized monoclonal antibody that binds to folate receptor-α, which is highly exp...

Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer

Kim, Kenneth H.
Jelovac, Danijela
Armstrong, Deborah K.
Schwartz, Benjamin
Weil, Susan C.
Schweizer, Charles
Alvarez, Ronald D.

January 2016

Farletuzumab is a humanized monoclonal antibody that binds to folate receptor alpha, over-expressed ...

Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer.

Herzog, Thomas J
Pignata, Sandro
Ghamande, Sharad A
Rubio, Maria-Jesús
Fujiwara, Keiichi
Vulsteke, Christof
Armstrong, Deborah K
Sehouli, Jalid
Coleman, Robert L
Gabra, Hani
Scambia, Giovanni
Monk, Bradley J
Arranz, José A
Ushijima, Kimio
Hanna, Rabbie
Zamagni, Claudio
Wenham, Robert M
González-Martín, Antionio
Slomovitz, Brian
Jia, Yan
Ramsay, Lisa
Tewari, Krishnansu S
Weil, Susan C
Vergote, Ignace B

March 2023

OBJECTIVE: The primary purpose of this study was to determine if farletuzumab, an antifolate recepto...

Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer

Kim, Kenneth H.
Jelovac, Danijela
Armstrong, Deborah K.
Schwartz, Benjamin
Weil, Susan C.
Schweizer, Charles
Alvarez, Ronald D.

February 2016

AbstractObjectiveFarletuzumab is a humanized monoclonal antibody that binds to folate receptor alpha...

PHASE I STUDIES

K. Miwa
K. Yamashita
N. Katsumata
H. Ishida

January 2014

A phase I study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients...

Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FR alpha)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer

O'Malley, David M
Matulonis, Ursula A
Birrer, Michael J
Castro, Cesar M
Gilbert, Lucy
Vergote, Ignace
Martin, Lainie P
Mantia-Smaldone, Gina M
Gonzalez Martin, Antonio
Bratos, Raquel
Penson, Richard T
Malek, Karim
Moore, Kathleen N

May 2020

PURPOSE: To evaluate the safety and clinical activity of mirvetuximab soravtansine, an antibody-drug...

Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FR alpha)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer

Moore, Kathleen N
O'Malley, David M
Vergote, Ignace
Martin, Lainie P
Gonzalez-Martin, Antonio
Malek, Karim
Birrer, Michael J

October 2018

PURPOSE: To evaluate the safety profile and preliminary antitumor activity of mirvetuximab soravtans...

A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer

Moore, Kathleen N
Martin, Lainie P
O'Malley, David M
Matulonis, Ursula A
Konner, Jason A
Vergote, Ignace
Ponte, Jose F
Birrer, Michael J

January 2018

Resistance to platinum-based therapy poses a significant clinical challenge for the management of ad...

Improved Intraoperative Detection of Ovarian Cancer by Folate Receptor Alpha Targeted Dual-Modality Imaging

Hekman, M.C.H.
Boerman, O.C.
Bos, D.L.
Massuger, L.F.
Weil, S.
Grasso, L.
Rybinski, K.A.
Oosterwijk, E.
Mulders, P.F.A.
Rijpkema, M.J.P.

January 2017

Contains fulltext : 177772.pdf (publisher's version ) (Open Access)Complete resect...

Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer

Bergamini, Alice
Ferrero, Simone
Leone Roberti Maggiore, Umberto
Scala, Carolina
Pella, Francesca
Vellone, Valerio Gaetano
Petrone, Micaela
Rabaiotti, Emanuela
Cioffi, Raffaella
Candiani, Massimo
Mangili, Giorgia

January 2016

The prognosis of patients affected by ovarian cancer has not substantially changed in the last decad...

Randomized Phase III Study of Erlotinib Versus Observation in Patients With No Evidence of Disease Progression After First-Line Platin-Based Chemotherapy for Ovarian Carcinoma: A European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup Study

Vergote, Ignace
Jimeno, Antonio
Joly, Florence
Katsaros, Dionyssios
Coens, Corneel
Despierre, Evelyn
Marth, Christian
Hall, Marcia
Steer, Christopher B
Colombo, Nicoletta
Lesoin, Anne
Casado, Antonio
Reinthaller, Alexander
Green, John
Buck, Martin
Ray-Coquard, Isabelle
Ferrero, Annamaria
Favier, Laure
Reed, Nick Simon
Curé, Hervé
Pujade-Lauraine, Eric

February 2014

This trial evaluated the efficacy of maintenance erlotinib, an epidermal growth factor receptor (EGF...

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial

Bois, Andreas du
Kristensen, Gunnar
Ray-Coquard, Isabelle
Reuss, Alexander
Pignata, Sandro
Colombo, Nicoletta
Denison, Ursula
Vergote, Ignace
Del Campo, Jose M
Ottevanger, Petronella
Heubner, Martin
Minarik, Thomas
Sevin, Emmanuel
de Gregorio, Nikolaus
Bidziński, Mariusz
Pfisterer, Jacobus
Malander, Susanne
Hilpert, Felix
Mirza, Mansoor R
Scambia, Giovanni
Meier, Werner
Nicoletto, Maria O
Bjørge, Line
Lortholary, Alain
Sailer, Martin Oliver
Merger, Michael
Harter, Philipp

January 2016

Angiogenesis is a target in the treatment of ovarian cancer. Nintedanib, an oral triple angiokinase ...

ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer

Marth, Christian
Vergote, Ignace
Scambia, Giovanni
Oberaigner, Willi
Clamp, Andrew
Berger, Regina
Kurzeder, Christian
Colombo, Nicoletta
Vuylsteke, Peter
Lorusso, Domenica
Hall, Marcia
Renard, Vincent
Pignata, Sandro
Kristeleit, Rebecca
Altintas, Sevilay
Rustin, Gordon
Wenham, Robert M
Mirza, Mansoor Raza
Fong, Peter C
Oza, Amit
Monk, Bradley J
Ma, Haijun
Vogl, Florian D
Bach, Bruce A

November 2016

Trebananib, a peptide-Fc fusion protein, inhibits angiogenesis by inhibiting binding of angiopoietin...

Farletuzumab for NSCLC: Exploiting a well-known metabolic pathway for a new therapeutic strategy

Bronte G.
Lo Vullo F.
Pernice G.
Galvano A.
Fiorentino E.
Cicero G.
Bazan V.
Rolfo C.
Russo A.

January 2015

Introduction: The therapeutic options for NSCLC are limited barring targeted drugs, such as EGFR tyr...

Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications

Vergote, Ignace
Marth, Christian
Coleman, Robert L

January 2015

Folate can be transported into the cell by the reduced folate carrier (RFC), the proton-coupled fola...

A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse

Vergote, Ignace
Armstrong, Deborah
Scambia, Giovanni
Teneriello, Michael
Sehouli, Jalid
Schweizer, Charles
Weil, Susan C
Bamias, Aristotelis
Fujiwara, Keiichi
Ochiai, Kazunori
Poole, Christopher
Gorbunova, Vera
Wang, Wenquan
O'Shannessy, Daniel
Herzog, Thomas J

July 2016

Farletuzumab is a humanized monoclonal antibody that binds to folate receptor-α, which is highly exp...

Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer

Kim, Kenneth H.
Jelovac, Danijela
Armstrong, Deborah K.
Schwartz, Benjamin
Weil, Susan C.
Schweizer, Charles
Alvarez, Ronald D.

January 2016

Farletuzumab is a humanized monoclonal antibody that binds to folate receptor alpha, over-expressed ...

Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer.

Herzog, Thomas J
Pignata, Sandro
Ghamande, Sharad A
Rubio, Maria-Jesús
Fujiwara, Keiichi
Vulsteke, Christof
Armstrong, Deborah K
Sehouli, Jalid
Coleman, Robert L
Gabra, Hani
Scambia, Giovanni
Monk, Bradley J
Arranz, José A
Ushijima, Kimio
Hanna, Rabbie
Zamagni, Claudio
Wenham, Robert M
González-Martín, Antionio
Slomovitz, Brian
Jia, Yan
Ramsay, Lisa
Tewari, Krishnansu S
Weil, Susan C
Vergote, Ignace B

March 2023

OBJECTIVE: The primary purpose of this study was to determine if farletuzumab, an antifolate recepto...

Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer

Kim, Kenneth H.
Jelovac, Danijela
Armstrong, Deborah K.
Schwartz, Benjamin
Weil, Susan C.
Schweizer, Charles
Alvarez, Ronald D.

February 2016

AbstractObjectiveFarletuzumab is a humanized monoclonal antibody that binds to folate receptor alpha...

PHASE I STUDIES

K. Miwa
K. Yamashita
N. Katsumata
H. Ishida

January 2014

A phase I study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients...

Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FR alpha)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer

O'Malley, David M
Matulonis, Ursula A
Birrer, Michael J
Castro, Cesar M
Gilbert, Lucy
Vergote, Ignace
Martin, Lainie P
Mantia-Smaldone, Gina M
Gonzalez Martin, Antonio
Bratos, Raquel
Penson, Richard T
Malek, Karim
Moore, Kathleen N

May 2020

PURPOSE: To evaluate the safety and clinical activity of mirvetuximab soravtansine, an antibody-drug...

Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FR alpha)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer

Moore, Kathleen N
O'Malley, David M
Vergote, Ignace
Martin, Lainie P
Gonzalez-Martin, Antonio
Malek, Karim
Birrer, Michael J

October 2018

PURPOSE: To evaluate the safety profile and preliminary antitumor activity of mirvetuximab soravtans...

A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer

Moore, Kathleen N
Martin, Lainie P
O'Malley, David M
Matulonis, Ursula A
Konner, Jason A
Vergote, Ignace
Ponte, Jose F
Birrer, Michael J

January 2018

Resistance to platinum-based therapy poses a significant clinical challenge for the management of ad...

Improved Intraoperative Detection of Ovarian Cancer by Folate Receptor Alpha Targeted Dual-Modality Imaging

Hekman, M.C.H.
Boerman, O.C.
Bos, D.L.
Massuger, L.F.
Weil, S.
Grasso, L.
Rybinski, K.A.
Oosterwijk, E.
Mulders, P.F.A.
Rijpkema, M.J.P.

January 2017

Contains fulltext : 177772.pdf (publisher's version ) (Open Access)Complete resect...

Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer

Bergamini, Alice
Ferrero, Simone
Leone Roberti Maggiore, Umberto
Scala, Carolina
Pella, Francesca
Vellone, Valerio Gaetano
Petrone, Micaela
Rabaiotti, Emanuela
Cioffi, Raffaella
Candiani, Massimo
Mangili, Giorgia

January 2016

The prognosis of patients affected by ovarian cancer has not substantially changed in the last decad...

Randomized Phase III Study of Erlotinib Versus Observation in Patients With No Evidence of Disease Progression After First-Line Platin-Based Chemotherapy for Ovarian Carcinoma: A European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup Study

Vergote, Ignace
Jimeno, Antonio
Joly, Florence
Katsaros, Dionyssios
Coens, Corneel
Despierre, Evelyn
Marth, Christian
Hall, Marcia
Steer, Christopher B
Colombo, Nicoletta
Lesoin, Anne
Casado, Antonio
Reinthaller, Alexander
Green, John
Buck, Martin
Ray-Coquard, Isabelle
Ferrero, Annamaria
Favier, Laure
Reed, Nick Simon
Curé, Hervé
Pujade-Lauraine, Eric

February 2014

This trial evaluated the efficacy of maintenance erlotinib, an epidermal growth factor receptor (EGF...

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial

Bois, Andreas du
Kristensen, Gunnar
Ray-Coquard, Isabelle
Reuss, Alexander
Pignata, Sandro
Colombo, Nicoletta
Denison, Ursula
Vergote, Ignace
Del Campo, Jose M
Ottevanger, Petronella
Heubner, Martin
Minarik, Thomas
Sevin, Emmanuel
de Gregorio, Nikolaus
Bidziński, Mariusz
Pfisterer, Jacobus
Malander, Susanne
Hilpert, Felix
Mirza, Mansoor R
Scambia, Giovanni
Meier, Werner
Nicoletto, Maria O
Bjørge, Line
Lortholary, Alain
Sailer, Martin Oliver
Merger, Michael
Harter, Philipp

January 2016

Angiogenesis is a target in the treatment of ovarian cancer. Nintedanib, an oral triple angiokinase ...

ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer

Marth, Christian
Vergote, Ignace
Scambia, Giovanni
Oberaigner, Willi
Clamp, Andrew
Berger, Regina
Kurzeder, Christian
Colombo, Nicoletta
Vuylsteke, Peter
Lorusso, Domenica
Hall, Marcia
Renard, Vincent
Pignata, Sandro
Kristeleit, Rebecca
Altintas, Sevilay
Rustin, Gordon
Wenham, Robert M
Mirza, Mansoor Raza
Fong, Peter C
Oza, Amit
Monk, Bradley J
Ma, Haijun
Vogl, Florian D
Bach, Bruce A

November 2016

Trebananib, a peptide-Fc fusion protein, inhibits angiogenesis by inhibiting binding of angiopoietin...

Farletuzumab for NSCLC: Exploiting a well-known metabolic pathway for a new therapeutic strategy

Bronte G.
Lo Vullo F.
Pernice G.
Galvano A.
Fiorentino E.
Cicero G.
Bazan V.
Rolfo C.
Russo A.

January 2015

Introduction: The therapeutic options for NSCLC are limited barring targeted drugs, such as EGFR tyr...

Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications

Vergote, Ignace
Marth, Christian
Coleman, Robert L

January 2015

Folate can be transported into the cell by the reduced folate carrier (RFC), the proton-coupled fola...

A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse

Abstract

Extracted data

A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse

Abstract

Extracted data

Related items

Related items